Despite Europe's thriving startup ecosystem, which consistently produces world-class scientific discoveries and breakthrough technologies, innovative enterprises face severe challenges when attempting to scale within the continent. As tech and life science companies transition from early-stage validation to the capital-intensive scaleup phase, they routinely encounter an underdeveloped late-stage venture capital sector. This domestic funding gap, particularly acute in growth